This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
In 2002, investigators from the University of Padua, Italy prospectively enrolled pregnant women with early (<17 week's gestation) primary cytomegalovirus (CMV) infection in a study to determine the efficacy of CMV hyperimmunoglobulin (HIG) therapy to prevent adverse congenital outcomes. Beginning in 2007, mothers primarily infected early in gestation were offered a single dose of CMV HIG treatment if their fetuses had CMV DNA detected by amniocentesis after week 20 of gestation and ≥6 weeks after maternal infection. HIG treatment was provided between 20 and 24 weeks of gestation. Mothers enrolled from 2002 to 2006 served as historical controls. The authors compared poor outcomes (defined as hemiparesis, motor retardation, hypertonia, hypotonia, seizures, spastic …
Individual Login
Institutional Login
You may be able to gain access using your login credentials for your institution. Contact your librarian or administrator if you do not have a username and password.
Log in through your institution
Purchase access
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.